Ece Sengun Filiz

Ece Sengun Filiz

Auto-generated profile, based on publicly available information

Ece Sengun Filiz

Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in European Eating Disorders Review
Verified
Journal Article
Open access
OSOlena Said
Olena Said
EFEce Sengun Filiz
Ece Sengun Filiz
DSDominic Stringer
Dominic Stringer
BABriana Applewhite
Briana Applewhite
VKVanessa Kellermann
Vanessa Kellermann
Hubertus HimmerichHubertus Himmerich
Hubertus Himmerich
Introduction: Antipsychotics are routinely prescribed off‐label for anorexia nervosa (AN) despite limited evidence. This article presents a protocol of a study aiming to assess the feasibility of a future definitive trial on olanzapine in young people with AN.Methods and analysis: In an open‐label, one‐armed feasibility study, 55 patients with AN or atypical AN, aged 12–24, receiving outpatient, inpatient or day‐care treatment who are considered for olanzapine treatment will be recruited from NHS sites based in England. Assessments will be conducted at screening, baseline and at 8‐, 16 weeks, 6‐ and 12 months. Primary feasibility parameters will be proportions of patients who agree to take olanzapine and who adhere to treatment and complete study assessments. Qualitative methods will be used to explore acceptability of the intervention and study design. Secondary feasibility parameters will be changes in body mass index, psychopathology, side effects, health‐related quality of life, carer burden and proportion of participants who would enrol in a future randomised controlled trial. The study is funded by the National Institute for Health Research via Health Technology Assessment programme.Discussion: Olanzapine for young PEople with aNorexia nervosa will inform a future randomised controlled trial on the efficacy and safety of prescribing olanzapine in young people with AN.

30 January 2026 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
EFEce Sengun Filiz
Ece Sengun Filiz
RPRadhika Patel
Radhika Patel
MHMatthew Hodes
Matthew Hodes
This review investigates the utilisation of specialist child and adolescent mental health services (CAMHS) among refugee and asylum-seeking children (<18 years) globally, compared to non-refugee peers, more specifically looking at differences in diagnostic and therapeutic profiles, service use referral pathways and barriers to access, and hospitalisation. A systematic search of MEDLINE, Embase, PsycINFO, and CINAHL was conducted from inception until August 8, 2025. Observational studies with quantitative outcomes comparing CAMHS use between refugee/asylum-seeking and non-refugee/non-asylum-seeking children were included. Eligible studies were quality-assessed using the Newcastle-Ottawa Scale and data was presented in a narrative synthesis due to heterogeneity. Twenty-five studies were included, mainly from high-income settings and of high quality. Refugee/asylum-seeking youth exhibited higher rates of PTSD, anxiety, and depression but lower outpatient CAMHS utilisation, compared to non-refugee/non-asylum-seeking peers. Refugees/asylum-seekers received fewer guideline-concordant treatments, particularly for ADHD and mood disorders. Refugees were more likely to be referred by non-medical agencies, compared to non-refugees. Barriers included language, stigma, fragmented primary care registration, and crisis-driven entry into services through emergency departments or social services rather than primary care. Findings on inpatient admissions yielded a mixed picture, with unaccompanied minors overrepresented in involuntary care. Results imply inequity in CAMHS contact among refugee youth, in the context of high need and despite lack of economic barriers. More timely and culturally sensitive access is needed, and effective training for non-medical agencies and responsive public policies that reduce structural barriers to psychiatric care and address the complex circumstances and needs of displaced youth. Systematic Review: Child and Adolescent Refugees and Asylum-Seekers' Contact with Specialist Mental Health Services; https://www.crd.york.ac.uk/PROSPERO/view/CRD42022310239.

1 May 2026 in Health Technology Assessment
Verified
Journal Article
Open access
EFEce Sengun Filiz
Ece Sengun Filiz
DSDominic Stringer
Dominic Stringer
VKVanessa Kellermann
Vanessa Kellermann
RORachel Rowan Olive
Rachel Rowan Olive
OSOlena Said
Olena Said
Hubertus HimmerichHubertus Himmerich
Hubertus Himmerich
Background: In clinical practice, olanzapine is commonly used in young people with anorexia nervosa, although the underpinning evidence-base is limited. However, its efficacy, tolerability, acceptability and adherence rate, and the patients’, carers’ and clinicians’ views of olanzapine treatment are unclear. This synopsis article summarises the methods and results of the OPEN feasibility study, overarching the findings and drawing comprehensive conclusions from a quantitative feasibility outcome paper and two qualitative research papers. Methods: The OPEN study assessed the feasibility of a future randomised controlled trial on olanzapine in young people with anorexia nervosa in an open-label, one-armed feasibility study. In this study, we aimed to include 55 patients with anorexia nervosa or atypical anorexia nervosa aged 12–24 who gained < 2 kg within at least 1 month of treatment as usual. Time points for assessments were at baseline, 8 weeks, 16 weeks, and 6 or 12 months. We estimated recruitment, adherence and attrition rates and mean changes in body weight, body mass index and eating disorder psychopathology. In addition, we explored the views on and experiences with olanzapine treatment within a clinical trial setting using qualitative interviews with young people with anorexia nervosa, their families and clinicians. Results: Fifty-two people were pre-screened, 35 were eligible and 20 participants were recruited and started olanzapine. Of these, 15 continued olanzapine for ≥ 16 weeks. Participants experienced, on average, a decrease in their eating disorder psychopathology, and body weight and body mass index increased during treatment with olanzapine as an adjunct to treatment as usual. Important themes derived from semi-structured qualitative interviews with young people and their parents were: moving away from the illness towards recovery, evaluating information on olanzapine, consent and trust in shared decision-making and the ambivalence around recovery. The main themes expressed by clinicians included: acknowledging the concerns of young people with anorexia nervosa and their families, prioritising person-centred care, the limited service capacity and strict study eligibility criteria. Limitations: The study failed to meet the recruitment target and showed low adherence rates for treatment with olanzapine. Possible reasons for the recruitment difficulties and the low adherence rate include the high clinical workload of eating disorder services during and after the COVID-19 pandemic, the heterogeneity of eating disorder service setup across the country, and the reluctance of patients to agree to take olanzapine under the relatively restricted conditions of a clinical study. Conclusions: A realistic time schedule for site-preparation, recruitment, treatment and follow-up, realistic recruitment targets and easy access to medical and laboratory examinations may improve the success of future feasibility studies and randomised controlled trials in this patient group. Future work: The difficulties in conducting the OPEN study will inform the planning for future pharmacological and non-pharmacological studies in anorexia nervosa. Therefore, we developed a checklist with action points for the planning of pharmacological trials in eating disorders. Furthermore, novel pharmacological options such as typical and atypical psychedelic drugs (e.g. psilocybin and ketamine) might be more acceptable for people with anorexia nervosa as they do not have the side effect of immediate weight gain. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR130780.